Duragesic Pediatric Exclusivity Decision Expected “Shortly,” Mylan Says
Executive Summary
Mylan expects to hear from FDA "shortly" on whether its generic version of Johnson & Johnson's Duragesic fentanyl patch will be delayed an additional six months due to a pediatric exclusivity extension